Joseph Ochipinti is the CEO of UnitedHealthcare Mid-Atlantic Region and has been in this role since early 2019.

Ochipinti brings over 25 years of health care and financial services experience. As CEO of UnitedHealthcare-Mid Atlantic, he is responsible for UnitedHealthcare’s Employer & Individual business driving growth, quality, profitability and overall performance for health benefit plans that serve more than 2.8million UHC members in Maryland, Virginia, West Virginia and District of Columbia. He is based at UnitedHealthcare’s Columbia, MD office.

Prior to 2019, Ochipinti served as CEO of United Healthcare Gulf States Region (LA, MS, AL) for a little over 3 years. Prior to 2016, Joe served as Chief Growth officer for3 years in the Southeast Region, responsible for sales and membership growth, profitability and account management. He also developed and executed business plans for Small Business, Key Account, Public Sector, Specialty and Individual Exchanges.

Previously, Ochipinti was Vice President of Sales of UnitedHealthcare’s Employer & Individual Gulf States Regionfrom 2009 to 2013, and from 2007 to 2009 he led the company’s medical, pharmacy and specialty product strategy in the Southeast Region.

Ochipinti has servedon the American Heart Association Heart Walk National Executive team since 2015and serves on the local and regional boards of the American Lung Association (ALA). In 2013 he advocated for the eventual passage of Smoke Free New Orleans, which made all workplaces throughout the city smoke-free.He serves on the Economic Council Executive Board and the local March of Dimes Board in DMV.

Joe is a graduate of LaSalle University in Philadelphia with a Bachelor of Arts degree in Industrial Public Relations. He received his Master’s Degree from Webster University School of Business & Technology in St Louisand is a graduate of the Wharton’s School of Business seven-month UnitedHealth Group Executive Development and General Management Program. He and his lovely wife Deirdre, have been married 15 years and have two wonderful children, Alec 11 and Kate 6.

than 15 years of progressive leadership across multi-billion-dollar health systems. He currently serves as Vice

President & Administrator of Ambulatory Operations and Physician & APP Services at Inova Health, where he

leads a $900M division encompassing 290+ ambulatory sites, 2,500 team members, and over 3.5 million annual

patient encounters. In this role, he partners closely with hospital and service line presidents to drive system

alignment, strategic growth, and high-performing care delivery.

Prior to Inova, Marque served as Assistant Vice President of Atrium Health’s Clinically Integrated Network in

Charlotte, NC, where he led strategy and performance for value-based care initiatives covering 660,000+ lives.

His earlier leadership at Loyola Medicine included practice integration, surgical operations, and system

redesign across both academic and community hospital environments.

Marque holds a Bachelor of Science in Industrial Engineering from Clemson University and an MBA in

Operations Management from Loyola University Chicago. He is a Fellow of the American College of Healthcare

Executives (FACHE) and a Certified Six Sigma Black Belt.

He currently serves as Regent for the American College of Healthcare Executives (DC & Northern Virginia) and

is a former Board Member of the Clemson University Alumni Association (2022–2025). Marque has also served

as President of the National Association of Health Services Executives – North Carolina Chapter and as adjunct

faculty at UNC Charlotte. He has been recognized by Modern Healthcare as a 2025 “40 Under 40” honoree and

by Becker’s Healthcare as one of the “75 Black Healthcare Leaders to Know.”

Originally from Gadsden, South Carolina, Marque is passionate about building inclusive, efficient, and people-

centered health systems that improve outcomes for all. Outside of work, he enjoys fitness, the outdoors, and

cheering on his Clemson Tigers.

Ben Stutz serves as the Director of Hospital and Health System Development for the District of

Columbia. He is also the Chief Operating Officer of the Department of Health Care

Finance (DHCF), the District’s Medicaid Agency.

In these roles, he leads the implementation of the first new hospital to be built in the

District of Columbia in over 25 years.  Opened on April 15, 2025, the 190-bed, $434

million, Cedar Hill Regional Medical Center, GW Health was completed on schedule and

within budget. The new hospital and health system was established through a public

private partnership between the District of Columbia and Universal Health Services, Inc.

Cedar Hill, named after Frederick Douglass’s historic residence in the Washington, D.C.

will be integrated with two new urgent and ambulatory care facilities, existing providers,

the George Washington University Hospital, the George Washing University School of

Medicine and Health Sciences and Children’s National, to establish a robust system of

care for all District residents and in particular, communities east of the Anacostia River,

whose life expectancy is 15 years below the City average.

As the Chief Operating Officer for DC Medicaid, Ben oversees the Human Resource,

Information Technology and Security, Procurement, and Building Management

Departments. These 70 staff support the District’s $5 billion Medicaid program,

delivering care to nearly 250,000 Washingtonians.

Previously, Ben was appointed to be Chief of Staff to the District of Columbia’s City

Administrator in the Executive Office of Mayor Muriel Bowser. As the Senior Advisor

to the City Administrator, he worked to oversee the day-to-day operations of city

government, including emergency, disaster, civil and COVID-19 responses, the District's

annual operating and capital budgets, performance management, and labor relations.

Ben has served in City, County, and State government in the Washington D.C.

Metropolitan Region since 2002.  He holds an MBA and BA in Government and Politics

from the University of Maryland and an MA in Peace of Justice Studies from the

University of San Diego. He lives with his son Noah in Washington, D.C.

Stacy BenEzra Bell is CWC’s Chief Financial Officer and a key member of the firm’s executive leadership team. She guides the company’s financial strategy and planning to support continued growth, operational excellence, and strong external partnerships across banking, legal, insurance, and more.

Stacy launched her career in the DMV as a CPA and auditor before expanding into financial planning and analysis across various industries. After spending ten years in New York, she returned to the region in 2008 and has called it home ever since. Most recently, she served as Assistant Vice President of Real Estate at Inova Health System, where she managed a real estate portfolio of more than 3 million square feet and led $150–200 million in design and construction projects each year. Before that, she played a key role in budgeting and capital planning on Inova’s Corporate Finance team.

She holds a Bachelor of Science in Commerce with a concentration in Accounting and significant coursework in Marketing from the University of Virginia, as well as an MBA with a concentration in Healthcare Administration.

Stacy is part of the Jewish Federation of Greater Washington’s Community Leaders Program, an active member of NAIOP VA, and an adjunct professor at George Mason University College of Public Health. She enjoys learning languages and playing music. She has three grown children and lives in Arlington, VA, with her husband, Brian, and their labradoodle.

Thank you again for thinking of us to participate in this event! Rob Rumer, our Investments Manager from the DC office, is interested in participating on one of the panels. Rob, please meet Elizabeth, the event producer for Bisnow. Elizabeth, please meet Rob.

Rob will bring a fresh perspective to investment / development topics – speaking to what health systems and developers / investors are looking for in healthcare space moving forward, state of the market in terms of pipeline and available MOB space, and how health systems can unlock capital to re-invest in higher yielding, core business lines and services – addressing the issue of rising costs.

His bio and headshot are attached. Please let me know if we can provide any additional information at this time.

With commercial real estate experience starting in 2005, Colliers Vice Chairman Adam Schindler specializes in business development and portfolio management, including financial planning, modeling and analysis for corporations, law firms and nonprofit organizations. Schindler’s practice focuses on aligning the needs of occupiers of space with strategic real estate solutions. Adam brings a unique perspective to a vast array of clients with his expertise in the market. His insight keeps him connected and he is able to expand his real estate knowledge not only in the DMV area, but nationally/internationally, as businesses he has worked with grow and look to him for assistance in their real estate needs. Prior to joining Colliers, Adam was a partner at Serten Advisors (acquired by Colliers in 2017).

Dr. Cherry received his doctorate in Biology with a concentration in Biomedical Science from The Catholic

University of America in 2008 and his Master of Science in Biotechnology from The Johns Hopkins University in

2000. In his dissertation research, Dr. Cherry studied molecular changes in ovarian tumor progression, and

identified several biomarkers that proved useful in early diagnosis of this disease that often eludes detection until

it has reached a very advanced stage. He joined QIAGEN Inc. in 2008 as a research fellow in their Gene Expression

Laboratory where he studied the role of miRNAs in various disease states and identified novel miRNA targets in

phosphodiesters in collaboration with the Center for Cancer Research at NCI. Following his fellowship, he was

promoted to a research scientist in QIAGEN’s research and development laboratory, where he proceeded to work

on QIAGEN’s genomic characterization platform, miScript, for miRNA detection, low and high-throughput miRNA

molecular profiling platform. In addition, he developed the automated applications for Q-PCR gene expression

miRNA/mRNA molecular profiling kit and supported the marketing applications to the biomedical research

community. This new product generated $6.8 million net sales in year one for QIAGEN Inc. in 2010. He was then

recruited back to the NIH/NCI in 2010 to become a Scientific Program Director and Assistant Project Officer of the

Advanced Technology Program (ATP), and the Contracting Officer’s Representative, level III, for the Operational

Technical Support Contract for the National Cancer Institute’s (NCI) and the National Institute of Health’s Division

of Intramural Research community. The ATP/CRTP is currently a $17million program that provides state-of-the-art

advanced technologies to the NIH principal investigators, postdoctoral and clinical fellows at NIH/NCI and other

federally funded research institutes. In 2011, Dr. Cherry co-developed a $4 million technology development arm

for the ATP/CRTP directorate. This program was established to promote a collaborative environment with the NIH

intramural community to develop innovative technologies in all areas of biomedical research including genomics,

proteomics, imaging (subcellular and cellular), nanotechnology, genetically engineered animals, veterinary

histology/pathology and bioinformatics. In 2013 his responsibilities pivoted from the ATP/CRTP to the Laboratory

of Animal Science Program (LASP). During his governmental oversight of the LASP, he has successfully

implemented and launched the NCI’s Gnotobiotic operations, Genomic Modification Core and the HIV reservoir

laboratory and continued the development of the LASP technology development effort. In 2018 Dr. Cherry

launched the first Biotechnology Fellowship at the Frederick National Laboratory for trainees looking to move their

career to biotech and pharm arena. Dr. Cherry currently serves as the scientific advisor for all high school,

undergraduate, graduate and capstone students at the NCI at Frederick campus. In 2021 Dr. Cherry was selected to

become the chief of NIAID’s Research technologies Branch and the Associate Director of Research Technologies

within NIAID. There he established an interdisciplinary resource that provides investigators access to leading-edge

technologies and specialized expertise that are fully integrated to study complex biological questions. The first

initiative launched in year one was the Integrated Data Sciences Section, IDSS. This program focuses on providing

scientific consultation, training, on computational and data science support through manuscript preparation. In

2022 Dr. Cherry was named chief of operations for the Center for Human Immunology Inflammation and

Autoimmunity, where he worked in full collaboration with the newly established scientific advisory board to

increase the visibility and accept 46 projects during his three-year tenure from 16 total from 2008 to 2021. Dr.

Cherry has been appointed to several scientific advisory boards representing NIAID/NIH for various universities in

the state of Maryland and currently serves Chair of Board of Governors for Shepherd University. Dr. Cherry has

been an associate professor at Hood College’s graduate program since 2017 and currently an adjunct professor at

Mount St. Mary’s University graduate program where he teaches Biomedical Ethics, Introduction to Cancer

Biology, Cell Biology, Protein Biochemistry and Advanced Technologies Genomics and Proteomics applications.

Erik is passionate about designing highly complex, innovative science environments that have a role in the development of life-changing solutions to global challenges.

Having two decades of experience in the planning and design of the country’s most complex laboratories, Erik has long-standing relationships with leaders in the academic, corporate and government research industries, and inspires project teams to tackle challenging laboratory requirements in unique ways. His expertise encompasses the design of facilities for many client types, including life sciences/biotech, pharmaceutical, vivaria, cGMP and preclinical discovery through developmental research. A well-known thought leader, Erik frequently presents and writes for professional organizations such as AALAS, ISPE and IFMA.